Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 1 min

Psychotropic polypharmacy in children and adolescents: trends, contributory factors, and potential solutions

AI Summary
  • Rising psychotropic polypharmacy in children and adolescents despite limited evidence of safety or efficacy.
  • Polypharmacy may pose greater risks in youth than adults, with unclear balance of benefits and harms.
  • Reduce polypharmacy through psychotherapy access, regular medication review, clinician and family education, oversight programmes, deprescribing guidelines, research and early intervention.
Summarise with AI (MRCPsych/FRANZCP)

Curr Opin Psychiatry. 2026 Nov 1;39(6):498-505. doi: 10.1097/YCO.0000000000001125. Epub 2026 Oct 1.

ABSTRACT

PURPOSE OF REVIEW: Lately, there have been concerns for psychotropic polypharmacy in children and adolescents, despite a lack of research and guidelines on psychotropic polypharmacy. This narrative review examines recent research on psychotropic polypharmacy in children and adolescents, risks, contributory factors, and potential solutions.

RECENT FINDINGS: Psychotropic polypharmacy in children and adolescents has increased, including that involving antipsychotic medications, despite a paucity of clear evidence on benefits of polypharmacy outweighing risks. Risks of psychotropic polypharmacy in youth may be greater than in adults. Contributory factors include limited availability of psychotherapy, psychiatric comorbidities, high severity, parent and physician-related factors, and inadequate awareness. Periodic review of medications, increased patient and clinician education, oversight programs, deprescribing guidelines, further research, and prevention and early intervention may help reduce psychotropic polypharmacy.

SUMMARY: Psychotropic polypharmacy has increased in children and adolescents, despite limited evidence on safety and efficacy. Reducing psychotropic polypharmacy requires a multipronged approach.

PMID:42937104 | DOI:10.1097/YCO.0000000000001125

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD